NRSN vs. IPSC, ONCY, BLUE, PRLD, IOBT, HOWL, IMRX, OPTN, KRON, and ACHL
Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Century Therapeutics (IPSC), Oncolytics Biotech (ONCY), bluebird bio (BLUE), Prelude Therapeutics (PRLD), IO Biotech (IOBT), Werewolf Therapeutics (HOWL), Immuneering (IMRX), OptiNose (OPTN), Kronos Bio (KRON), and Achilles Therapeutics (ACHL). These companies are all part of the "pharmaceutical products" industry.
NeuroSense Therapeutics vs.
NeuroSense Therapeutics (NASDAQ:NRSN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.
NeuroSense Therapeutics has higher earnings, but lower revenue than Century Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.
Century Therapeutics received 35 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. Likewise, 67.27% of users gave Century Therapeutics an outperform vote while only 66.67% of users gave NeuroSense Therapeutics an outperform vote.
NeuroSense Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
In the previous week, Century Therapeutics had 8 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 9 mentions for Century Therapeutics and 1 mentions for NeuroSense Therapeutics. Century Therapeutics' average media sentiment score of 1.08 beat NeuroSense Therapeutics' score of 1.00 indicating that Century Therapeutics is being referred to more favorably in the news media.
Century Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,191.16%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than NeuroSense Therapeutics.
NeuroSense Therapeutics has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. NeuroSense Therapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity.
1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 6.8% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
Century Therapeutics beats NeuroSense Therapeutics on 12 of the 17 factors compared between the two stocks.
Get NeuroSense Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
NeuroSense Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NRSN) was last updated on 2/17/2025 by MarketBeat.com Staff